Research & Development

FDA approves GSK’s Wellcovorin for cerebral folate deficiency

The US Food and Drug Administration (FDA) has granted its approval for the expanded use of GSK’s Wellcovorin (leucovorin calcium) tablets to treat cerebral folate deficiency (CFD) in patients with a confirmed variant in the folate receptor one (FOLR1) gene.

NewcelX and Eledon partner for NCEL-101 programme

NewcelX has signed a collaborative research agreement with Eledon Pharmaceuticals to advance its NCEL-101 programme for type 1 diabetes (T1D).

Sciwind secures China’s NMPA approval for Ecnoglutide injection

Sciwind Biosciences has received China’s National Medical Products Administration (NMPA) approval for its Ecnoglutide injection for chronic weight management.

J&J announces Tecvayli-Darzalex combo approval from FDA for multiple myeloma

Johnson & Johnson (J&J) has announced the US Food and Drug Administration (FDA) approval for the combination of Tecvayli (teclistamab-cqyv) and Darzalex Faspro (daratumumab and hyaluronidase-fihj) for adults with relapsed or refractory multiple myeloma (r/r MM).

Liberate Bio gains licences for myeloid-specific CAR design patents

Liberate Bio has obtained both exclusive and non-exclusive licences for patents related to chimeric antigen receptor (CAR) designs tailored for myeloid cells, such as monocytes and macrophages.

Aspire Biopharma and Microsize collaborate for alprazolam powder formulation

Aspire Biopharma has entered a strategic partnership with Microsize to advance the development of a new sublingual powder formulation of alprazolam, targeting rapid anxiety relief.

Esperion to acquire Corstasis for cardiovascular franchise expansion

Esperion Therapeutics has signed a definitive agreement to acquire Corstasis Therapeutics to expand its cardiovascular franchise with the addition of Enbumyst, a bumetanide nasal spray.

Rallybio to acquire Candid Therapeutics

US-based biotechnology company Rallybio has entered a definitive agreement to acquire Candid Therapeutics through a merger transaction.

Kairos Pharma signs deal for Celyn Therapeutics’ CL-273

Kairos Pharma has signed a binding agreement to acquire exclusive worldwide rights to CL-273 from Celyn Therapeutics, a company backed by OrbiMed and Torrey Pines Investment.